Trial Profile
Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2016
Price :
$35
*
At a glance
- Drugs K 312 (Primary)
- Indications Dyslipidaemias; Hyperlipidaemia
- Focus Pharmacokinetics
- Sponsors Kowa Research Institute
- 16 Feb 2016 New trial record